Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2002016356) QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS)
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2002/016356 International Application No.: PCT/US2001/021136
Publication Date: 28.02.2002 International Filing Date: 17.08.2001
Chapter 2 Demand Filed: 11.02.2002
IPC:
C07D 453/02 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
453
Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
02
containing not further condensed quinuclidine ring systems
Applicants:
MYERS, Jason, K. [US/US]; US (UsOnly)
GROPPI, Vincent, E., Jr. [US/US]; US (UsOnly)
PIOTROWSKI, David, W. [US/US]; US (UsOnly)
PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street Kalamazoo, MI 49001, US (AllExceptUS)
Inventors:
MYERS, Jason, K.; US
GROPPI, Vincent, E., Jr.; US
PIOTROWSKI, David, W.; US
Agent:
HOSLEY, Mary, J.; Pharmacia & Upjohn Company Intellectual Property Legal Services 301 Henrietta Street Kalamazoo, MI 49001, US
PERRY, Robert, Edward; Gill Jennings & Every Broadgate House 7 Eldon Street London EC2M 7LH, GB
Priority Data:
60/226,16418.08.2000US
60/284,95619.04.2001US
60/284,96819.04.2001US
60/284,97119.04.2001US
Title (EN) QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS)
(FR) COMPOSES ARYLE SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES
Abstract:
(EN) The invention provides compounds of Formula (I). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in which $g(a)7 is known to be involved.
(FR) L'invention concerne des composés représentés par la formule (I), qui peuvent se présenter sous la forme de sels ou de compositions pharmaceutiques et de mélanges racémiques ou d'énantiomères purs desdits sels ou compositions. Ces composés représentés par la formule (I) sont utiles dans des produits pharmaceutiques dans lesquels on sait que $g(a)7 joue un rôle.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)